Page last updated: 2024-12-07

brl 35135

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BRL 35135: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122186
CHEMBL ID49289
SCHEMBL ID4611391
MeSH IDM0174460

Synonyms (14)

Synonym
brl35135a
methyl 4-(2-(2-hydroxy-2-(3-chlorophenyl)ethylamino)propyl)phenoxyacetate
brl 35135
acetic acid, (4-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-, methyl ester
CHEMBL49289
L003499
91097-81-3
SCHEMBL4611391
n-[2-(4-carbomethoxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-chlorophenyl) ethanamine
methyl 4-[2-[(3-chloro-beta-hydroxyphenethyl) amino]propyl]phenoxyacetate
ZFLBZHXQAMUEFS-UHFFFAOYSA-N
4-[2-(2-(3-chlorophenyl)-2-hydroxyethylamino)propyl]phenoxya cetic acid methyl ester
DTXSID90919975
methyl [4-(2-{[2-(3-chlorophenyl)-2-hydroxyethyl]amino}propyl)phenoxy]acetate

Research Excerpts

Overview

BRL 35135 is a novel oral agent. When dosed chronically to obese rodents with abnormal glucose tolerance, improves insulin sensitivity and glucose tolerance.

ExcerptReferenceRelevance
"BRL 35135 is a novel oral agent which, when dosed chronically to obese rodents with abnormal glucose tolerance, improves both insulin sensitivity and glucose tolerance. "( Effects of BRL 35135, a beta-adrenoceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects.
Cawthorne, MA; Ellis, RD; Mitchell, TH; Robb, G; Smith, SA, 1989
)
2.11

Treatment

BRL 35135 treatment doubled BAT uncoupling protein mRNA levels (p < 0.05), and increased core temperature by 0.4 degree C. Treatment with BRL 35 135 reduced weight gain by 19%, increased brown adipose tissue thermogenic activity 45-fold and reduced plasma insulin by 50%.

ExcerptReferenceRelevance
"BRL 35135 treatment doubled BAT uncoupling protein mRNA levels (p < 0.05), and increased core temperature by 0.4 degree C (p < 0.05), but neither hypothalamic regional NPY levels nor hypothalamic NPY mRNA levels were affected by BRL 35135."( Direct stimulation of BAT thermogenesis does not affect hypothalamic neuropeptide Y.
Bing, C; Buckingham, R; Frankish, H; Hopkins, D; Wang, Q; Williams, G, 1998
)
1.02
"BRL 35135 treatment increased expression levels of beta3-AR mRNA in both genotypes."( The effects of the beta3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA expression.
Cawthorne, MA; Emilsson, V; Hamilton, S; Liu, YL; Summers, RJ, 1998
)
1.28
"3. Treatment with BRL 35135 reduced weight gain by 19%, increased brown adipose tissue thermogenic activity 45-fold and reduced plasma insulin by 50%."( Potentiation of the anti-obesity effect of the selective beta 3-adrenoceptor agonist BRL 35135 in obese Zucker rats by exercise.
Hänninen, V; Huupponen, R; Jhanwar-Uniyal, M; Koulu, M; Pesonen, U; Rouru, J; Santti, E, 1994
)
0.84

Dosage Studied

BRL 35135 improves both insulin sensitivity and glucose tolerance in obese rodents. Activation of thermogenesis with the selective beta 3-agonist reduced heat influx by both obese and lean rats at doses between 2 and 10 micrograms/kg. No dose-response effects were evident.

ExcerptRelevanceReference
"BRL 35135 is a novel oral agent which, when dosed chronically to obese rodents with abnormal glucose tolerance, improves both insulin sensitivity and glucose tolerance."( Effects of BRL 35135, a beta-adrenoceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects.
Cawthorne, MA; Ellis, RD; Mitchell, TH; Robb, G; Smith, SA, 1989
)
2.11
" Activation of thermogenesis with the selective beta 3-agonist BRL 35135 (BRL) reduced heat influx by both obese and lean rats at doses between 2 and 10 micrograms/kg, but no dose-response effects were evident within this range."( Effects of beta-adrenoceptor agonists and antagonists on thermoregulation in the cold in lean and obese Zucker rats.
Carlisle, HJ; Dubuc, PU; Stock, MJ, 1993
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID235309Ratio of the dose raising the rat heart rate to 500bpm, to ED50 for inhibition of GDP binding to beta-3 adrenergic receptor1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates.
AID41942Inhibition of beta-3 adrenergic receptor GDP binding in rat brown adipose tissue on oral administration relative to isoprenaline1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates.
AID41943Dose necessary to produce 50% of the isoprenaline effect to inhibit GDP binding to beta-3 adrenergic receptor in brown adipose tissue (BAT mitochondria) of rats after subcutaneous administration.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates.
AID235307Ratio of the dose (D500,peroral administration) elevating the rat heart rate to 500 bpm to the GDP ED50.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.63)18.7374
1990's32 (84.21)18.2507
2000's4 (10.53)29.6817
2010's1 (2.63)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.55 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index6.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (7.89%)5.53%
Reviews1 (2.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (89.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]